BSE · 533212 · FMCG
GKB Ophthalmics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹-2 Cr — a -29.37% net margin, versus 22.48% the period before.
Shareholding
As of 2026-06-30
- Promoter51.15%
- Public47.07%
- FII1.79%
2,557 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.03× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Personal Care - Indian · ranked #11 of 14 by market cap · medians across 12 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Godrej Consumer Products Ltd. | ₹1,10,152 Cr | 243.55 | 8.71 | 14.71% | 12.16% |
| Lenskart Solutions Ltd. | ₹97,308 Cr | 478.33 | 11.12 | 5.65% | 5.6% |
| Dabur India Ltd. | ₹76,936 Cr | 208.51 | 6.74 | 16.59% | 14.36% |
| Cupid Limited | ₹31,434 Cr | 865.81 | 69.73 | 24.01% | 30.26% |
| Emami Limited | ₹17,803 Cr | 124.34 | 6.09 | 26.51% | 20.51% |
| Jyothy Labs Limited | ₹7,572 Cr | 112.06 | 4.77 | 18.07% | 13.01% |
| Bajaj Consumer Care Ltd. | ₹7,008 Cr | 112.95 | 9.28 | 25.19% | 16.49% |
| Radix Industries (India) Ltd. | ₹225 Cr | 77 | 9.67 | 13.72% | 6.41% |
| Thrive Future Habitats Limited | ₹93 Cr | — | 1.76 | -1.94% | -85.25% |
| JHS Svendgaard Laboratories Ltd. | ₹65 Cr | — | 0.37 | -1.1% | -1.89% |
| GKB Ophthalmics Ltd.(this company) | ₹29 Cr | 150 | 0.54 | 5.53% | 0.81% |
AI analysis
AI-generated · google/gemini-2.5-flashGKB Ophthalmics Ltd. is listed on the Indian markets with a market capitalization of Rs 30 Cr. The company reported a revenue of Rs 110.32 Cr and a profit margin of 81.2%. Its current PE ratio stands at 156.47, with an EPS of 5.79. The book value per share is Rs 104.81.
Positives
- +The profit margin is high at 81.2%.
- +The debt-to-equity ratio is low at 0.23.
- +Promoter holding is above 50% at 51.15% as of June 30, 2026.
- +No promoter shares are pledged, with a promoter pledge percentage of 0%.
Negatives
- −The PE ratio of 156.47 is high.
- −Return on Equity (ROE) is low at 5.53%.
- −The company's reported net profit declined from Rs 0.44 Cr in Dec 2025 to Rs 0.19 Cr in Mar 2026.
- −Quarterly revenue decreased from Rs 56.79 Cr in Dec 2025 to Rs 29.79 Cr in Mar 2026.
- −The company's dividend yield is 0%.
Financial performance
GKB Ophthalmics Ltd. reported a revenue of Rs 110.32 Cr. Quarterly revenue for Mar 2026 was Rs 29.79 Cr, showing a decline from the Rs 56.79 Cr reported in Dec 2025. The company's net profit in Mar 2026 was Rs 0.19 Cr, following a profit of Rs 0.44 Cr in Dec 2025.
Profitability & returns
The company's overall profit margin was 81.2%. Return on equity (ROE) was 5.53% and return on capital employed (ROCE) was 11.74%. The EPS for the latest period stands at Rs 5.79. In Mar 2026, the company reported a net profit of Rs 0.19 Cr.
Balance sheet
GKB Ophthalmics Ltd. has a debt-to-equity ratio of 0.23, indicating a low level of debt relative to equity. The book value per share is Rs 104.81. No further details on assets or liabilities are provided in the available data.
Ownership & pledges
As of June 30, 2026, promoters held 51.15% of the shares. Public shareholding was 47.07%, while FIIs held 1.79%. There were no promoter shares reported as pledged. The company has a total of 2557 shareholders.
Regulatory & surveillance
There is no information available regarding any regulatory actions or surveillance measures against GKB Ophthalmics Ltd. The latest shareholding data is from June 30, 2026, with no reported pledges by promoters.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.